Download all the datasets for Covid-19 in BindingDB:  
BindingDB_Covid-19_2D_202402_sdf.zip
BindingDB_Covid-19_3D_202402_sdf.zip
BindingDB_Covid-19_202402_tsv.zip

  1. PMID
    Data
    Article Title
    Citation
    Organization
    Deposition
    Files Download
  2. Compounds and pharmaceutical uses thereofBDB
    US Patent US11793823 (2023)
    Syneurx International (Taiwan
    12/05/23
  3. NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTSBDB
    US Patent US20230331734 (2023)
    Enanta Pharmaceuticals
    12/01/23
  4. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.BDB
    Science 382: (2023)
    Cornell University
    11/27/23
  5. Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection.EBI
    Bioorg Med Chem 48: (2021)
    Kingston University
    06/26/23
  6. Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.EBI
    J Med Chem 65: 7682-7696 (2022)
    University Of Oxford
    06/25/23
  7. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.EBI
    J Med Chem 65: 6499-6512 (2022)
    Shionogi Pharmaceutical Research Center
    06/25/23
  8. Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.EBI
    J Med Chem 65: 7818-7832 (2022)
    Wichita State University
    06/25/23
  9. The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.EBI
    J Med Chem 64: 3508-3545 (2021)
    Niddk
    06/24/23
  10. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.EBI
    J Med Chem 65: 2848-2865 (2022)
    The University Of Arizona
    06/24/23
  11. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.EBI
    J Med Chem 65: 16902-16917 (2022)
    Shandong University
    06/24/23
  12. Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 1388-1389 (2022)
    Experimental Drug Development Centre
    06/24/23
  13. Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase.EBI
    ACS Med Chem Lett 13: 1477-1484 (2022)
    University Of Minnesota
    06/24/23
  14. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.EBI
    J Med Chem 65: 16252-16267 (2022)
    China Pharmaceutical University
    06/24/23
  15. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.EBI
    Eur J Med Chem 231: (2022)
    Shanghai Institute Of Materia Medica
    06/24/23
  16. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLEBI
    Eur J Med Chem 228: (2022)
    Shanghai University Of Traditional Chinese Medicine
    06/24/23
  17. Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (MEBI
    Bioorg Med Chem Lett 66: (2022)
    University Of Colorado
    06/23/23
  18. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.EBI
    Eur J Med Chem 238: (2022)
    Peking University
    06/23/23
  19. The Natural Products Withaferin A and Withanone from the Medicinal Herb EBI
    J Nat Prod 85: 2340-2350 (2022)
    Shiv Nadar University
    06/23/23
  20. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.EBI
    Bioorg Med Chem Lett 62: (2022)
    Australian National University
    06/23/23
  21. Discovery of highly potent SARS-CoV-2 MEBI
    Bioorg Med Chem Lett 58: (2022)
    Nanjing University Of Chinese Medicine
    06/23/23
  22. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.EBI
    J Med Chem 65: 8686-8698 (2022)
    Texas A&M University
    06/23/23
  23. A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.EBI
    ACS Med Chem Lett 13: 1345-1350 (2022)
    Experimental Drug Development Centre
    06/23/23
  24. Novel Halomethylketone Azadipeptides for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 875-876 (2022)
    A*Star
    06/22/23
  25. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.EBI
    J Med Chem 65: 9376-9395 (2022)
    Eberhard Karls University T£Bingen
    06/22/23
  26. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.EBI
    J Med Chem 65: 955-982 (2022)
    Eberhard Karls University T£Bingen
    06/22/23
  27. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.EBI
    J Med Chem 65: 7561-7580 (2022)
    The State University Of New Jersey
    06/22/23
  28. Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity.EBI
    ACS Med Chem Lett 13: 855-864 (2022)
    University Of Perugia
    06/22/23
  29. Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.EBI
    J Med Chem 65: 2716-2746 (2022)
    University Of Naples "Federico Ii
    06/22/23
  30. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.EBI
    Eur J Med Chem 238: (2022)
    Nankai University
    06/22/23
  31. Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.EBI
    ACS Med Chem Lett 13: 1394-1396 (2022)
    Experimental Drug Development Centre
    06/21/23
  32. Chemo- and Site-Selective Lysine Modification of Peptides and Proteins under Native Conditions Using the Water-Soluble Zolinium.EBI
    J Med Chem 65: 11840-11853 (2022)
    Chinese Academy Of Sciences
    06/21/23
  33. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.EBI
    RSC Med Chem 12: 1722-1730 (2021)
    University Of Alberta Edmonton
    06/21/23
  34. Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral EBI
    J Nat Prod 85: 1315-1323 (2022)
    University Of South Florida
    06/21/23
  35. Aspulvins A-H, Aspulvinone Analogues with SARS-CoV-2 MEBI
    J Nat Prod 85: 878-887 (2022)
    Yunnan University
    06/21/23
  36. Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.EBI
    Eur J Med Chem 240: (2022)
    Heidelberg University
    06/20/23
  37. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.EBI
    J Med Chem 65: 13852-13865 (2022)
    Kyushu University
    06/20/23
  38. Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.EBI
    J Med Chem 65: 13328-13342 (2022)
    Bio-Techne (Tocris)
    06/20/23
  39. Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.EBI
    Bioorg Med Chem Lett 72: (2022)
    New York University Abu Dhabi
    06/20/23
  40. A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.EBI
    Eur J Med Chem 240: (2022)
    Texas A&M University
    06/20/23
  41. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.EBI
    Eur J Med Chem 240: (2022)
    Texas A&M University
    06/20/23
  42. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.EBI
    Eur J Med Chem 240: (2022)
    Mazandaran University Of Medical Sciences
    06/19/23
  43. Advanced approaches of developing targeted covalent drugs.EBI
    RSC Med Chem 13: 1460-1475 (2022)
    College Of Pharmacy
    06/19/23
  44. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.EBI
    Bioorg Med Chem 29: (2021)
    Jadavpur University
    06/18/23
  45. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.EBI
    J Med Chem 65: 13343-13364 (2022)
    Shandong University
    06/18/23
  46. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.EBI
    J Nat Prod 84: 161-182 (2021)
    University Of California San Diego
    06/18/23
  47. Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen.EBI
    J Med Chem 65: 15227-15237 (2022)
    University Of Science And Technology Of China
    06/18/23
  48. Anti-SARS-CoV-2 Activity of EBI
    J Nat Prod 84: 1261-1270 (2021)
    Mahidol University
    06/18/23
  49. 3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds and preparation method and application thereofBDB
    US Patent US11612603 (2023)
    Shaanxi Panlong Pharmaceutical
    05/09/23
  50. Protacs targeting coronavirus 3CL protease and preparation method and application thereofBDB
    US Patent US11530195 (2022)
    Shaanxi Panlong Pharmaceutical
    02/16/23
  51. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11524940 (2022)
    Pardes Biosciences
    02/12/23
  52. Protacs based on VHL ligand targeting coronavirus 3CL protease and preparation method and application thereofBDB
    US Patent US11518759 (2022)
    Shaanxi Panlong Pharmaceutical
    02/05/23
  53. ETHER-LINKED ANTIVIRAL COMPOUNDSBDB
    WIPO WO2022208262 (2022)
    Pfizer
    01/31/23
  54. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASESBDB
    WIPO WO2022224223 (2022)
    Novartis
    01/31/23
  55. CORONAVIRUS MAIN PROTEASE INHIBITORS AND METHODS USING SAMEBDB
    WIPO WO2023004291 (2023)
    Baylor College Of Medicine
    01/31/23
  56. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11472793 (2022)
    Pardes Biosciences
    12/24/22
  57. SARS-COV-2 MPRO INHIBITOR COMPOUNDSBDB
    WIPO WO2022129953 (2022)
    Heptares Therapeutics
    10/05/22
  58. Spiropyrrolidine derived antiviral agentsBDB
    US Patent US11339170 (2022)
    Enanta Pharmaceuticals
    08/29/22
  59. Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.EBI
    Eur J Med Chem 223: (2021)
    Chinese Academy Of Medical Science And Peking Union Medical College
    08/23/22
  60. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.EBI
    Bioorg Med Chem Lett 43: (2021)
    Bristol University
    08/20/22
  61. Discovery and structural optimization of 3-O-?-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections.EBI
    Eur J Med Chem 215: (2021)
    South China Agricultural University
    08/19/22
  62. Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.EBI
    Bioorg Med Chem Lett 50: (2021)
    Australian National University
    08/19/22
  63. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11312704 (2022)
    Pardes Biosciences
    08/06/22
  64. ANTIVIRAL HETEROARYL KETONE DERIVATIVESBDB
    WIPO WO2022013684 (2022)
    Pfizer
    06/09/22
  65. NOVEL CORONAVIRUS MAIN PROTEASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOFBDB
    WIPO WO2022021841 (2022)
    Sichuan University
    06/09/22
  66. PHOSPHOLIPID COMPOUNDS AND USES THEREOFBDB
    WIPO WO2022081973 (2022)
    Gilead Sciences
    05/24/22
  67. Potent Inhibition of SARS-CoV-2 nsp14 BDB
    J Med Chem 65: 6231-6249 (2022)
    University Of Montpellier
    05/17/22
  68. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.BDB
    Nature (2022)
    University Of British Columbia
    03/30/22
  69. Aminocarbamoyl compounds for the treatment of viral infectionsBDB
    WIPO WO2022043374 (2022)
    F. Hoffmann-La Roche
    03/30/22
  70. Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).EBI
    J Med Chem 63: 13205-13227 (2020)
    South China Agricultural University
    03/27/22
  71. Druggable targets from coronaviruses for designing new antiviral drugs.EBI
    Bioorg Med Chem 28: (2020)
    Federal University Of Alagoas
    03/27/22
  72. Substituted nucleosides, nucleotides and analogs thereofBDB
    US Patent US11149049 (2021)
    Janssen Biopharma
    03/13/22
  73.  
    Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19BDB
    bioRxiv 2022: (2022)
    Shionogi Pharmaceutical Research Center
    02/02/22
  74. Perspectives on SARS-CoV-2 Main Protease Inhibitors.BDB
    J Med Chem 64: 16922-16955 (2021)
    Michigan State University
    01/27/22
  75. Sars-cov-2 inhibitors having covalent modifications for treating coronavirus infectionsBDB
    WIPO WO2021219089 (2021)
    Insilico Medicine Ip
    01/27/22
  76. Inhibitors of cysteine proteases and methods of use thereofBDB
    US Patent US11124497 (2021)
    Pardes Biosciences
    01/13/22
  77. Nitrile-containing antiviral compoundsBDB
    WIPO WO2021250648 (2021)
    Pfizer
    01/13/22
  78. Compounds and method of treating covid-19BDB
    WIPO WO2021205290 (2021)
    Pfizer
    01/13/22
  79. Compounds and methods for the treatment of covid-19BDB
    WIPO WO2021205298 (2021)
    Pfizer
    01/13/22
  80. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.BDB
    J Am Chem Soc 143: 20697-20709 (2021)
    The University Of Arizona
    01/13/22
  81. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.BDB
    J Med Chem 64: 14702-14714 (2021)
    Purdue University
    11/05/21
  82.  
    An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19BDB
    Science 374: 1-13 (2021)
    Pfizer
    11/05/21
  83. A patent review on SARS coronavirus main protease (3CLpro) inhibitors.BDB
    ChemMedChem (2021)
    Experimental Drug Development Centre
    11/05/21
  84. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity.BDB
    J Med Chem (2021)
    University Of Illinois At Chicago
    11/05/21
  85.  
    Open Science Discovery of Oral Non-Covalent SARS-CoV-2 Main Protease Inhibitor TherapeuticsBDB
    bioRxiv 2021: (2021)
    Israel Institution Of Biological Research
    11/05/21
  86. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 MBDB
    Proc Natl Acad Sci U S A 118: (2021)
    Baylor College Of Medicine
    09/11/21
  87. Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.BDB
    ACS Med Chem Lett 12: 1325-1332 (2021)
    Yale University
    09/10/21
  88. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.BDB
    ACS Pharmacol Transl Sci 4: 1408-1421 (2021)
    The University Of Arizona
    09/10/21
  89. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLBDB
    J Med Chem 65: 2880-2904 (2021)
    Cleveland Clinic
    08/14/21
  90. Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.EBI
    J Med Chem 63: 7491-7507 (2020)
    Qpex Biopharma
    08/13/21
  91. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.BDB
    Bioorg Med Chem Lett 48: 128263 (2021)
    A*Star
    07/29/21
  92. Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease.BDB
    J Med Chem 64: 10047-10058 (2021)
    Wichita State University
    07/29/21
  93. Peptidomimetic ?-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and BDB
    J Med Chem (2021)
    University Of Alberta
    07/29/21
  94. Highly active compounds against COVID-19BDB
    US Patent US10874687 (2020)
    Atea Pharmaceuticals
    07/25/21
  95. N4-hydroxycytidine and derivatives and anti-viral uses related theretoBDB
    US Patent US10874683 (2020)
    Emory University
    07/25/21
  96. SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse modelBDB
    Science (2021)
    Sichuan University
    02/28/21
  97.  
    Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation CalculationsBDB
    ACS Cent Sci (2021)
    Yale University
    02/28/21
  98. Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.EBI
    Bioorg Med Chem 27: 1981-1989 (2019)
    University Of Illinois At Chicago
    02/24/21
  99. The Other Angiotensin II Receptor: ATEBI
    J Med Chem 63: 1978-1995 (2020)
    Centre Hospitalier Universitaire Vaudois (Chuv) And University Of Lausanne (Unil
    02/21/21
  100.  
    Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screenBDB
    bioRxiv 2020: (2020)
    Fraunhofer Institute For Translational Medicine And Pharmacology (Itmp) And Fraunhofer Cluster Of Excellence For Immune Mediated Diseases (Cimd
    01/31/21
  101. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease InhibitorsBDB
    ChemMedChem (2020)
    Texas A&M University
    01/31/21
  102. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
    WIPO WO2006061714 (2006)
    Pfizer
    01/31/21
  103.  
    Inhibition of SARS-CoV-2 main protease by allosteric drug-bindingBDB
    bioRxiv 2020: (2020)
    Center For Free-Electron Laser Science
    01/31/21
  104. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.BDB
    Antimicrob Agents Chemother 64: (2020)
    Institut Pasteur Korea
    11/13/20
  105. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.BDB
    Sci Transl Med 12: 1-15 (2020)
    University Of North Carolina At Chapel Hill
    11/13/20
  106. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.BDB
    J Med Chem 59: 6595-628 (2016)
    University Of Bonn
    11/07/20
  107. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.BDB
    Med Res Rev (2020)
    University Of Bonn
    11/07/20
  108. Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesisBDB
    WIPO WO2005113580 (2005)
    Pfizer
    10/17/20
  109. Broad-spectrum non-covalent coronavirus protease inhibitorsBDB
    US Patent US9975885 (2018)
    Purdue Research Foundation
    09/25/20
  110. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19.BDB
    bioRxiv (2020)
    Pfizer
    09/21/20
  111.  
    Discovery of potent inhibitors of PLproCoV2 by screening a library of selenium-containing compoundsBDB
    bioRxiv 1-12 (2020)
    University Ofamsterdam
    09/21/20
  112. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.BDB
    Science 368: 1331-1335 (2020)
    Shanghai Institute Of Materia Medica
    09/21/20
  113. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors.BDB
    Science 368: 409-412 (2020)
    University Of Lubeck
    09/21/20
  114. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.BDB
    bioRxiv (2020)
    National Institutes Of Health
    09/21/20
  115. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.BDB
    ACS Infect Dis 6: 2099-2109 (2020)
    University Of Georgia
    09/21/20
  116. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.BDB
    Cancer Discov 4: 1310-25 (2014)
    Fred Hutchinson Cancer Research Center
    09/21/20
  117. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.BDB
    Biochem Biophys Res Commun 333: 194-9 (2005)
    National Taiwan University
    09/21/20
  118. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.BDB
    Sci Transl Med 12: (2020)
    Wichita State University
    09/06/20
  119. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors BDB
    Nature 582: 289-293 (2020)
    Shanghaitech University
    09/06/20
  120. Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.EBI
    Bioorg Med Chem 22: 167-77 (2014)
    University Of Illinois At Chicago
    09/02/20
  121. Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.EBI
    Bioorg Med Chem 22: 292-302 (2014)
    Tianjin University Of Science And Technology
    09/02/20
  122. Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.EBI
    Bioorg Med Chem Lett 23: 6317-20 (2013)
    Kansas State University
    09/01/20
  123. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.EBI
    Bioorg Med Chem 21: 3730-7 (2013)
    Korea Research Institute Of Bioscience And Biotechnology
    09/01/20
  124. Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases.EBI
    Eur J Med Chem 59: 1-6 (2013)
    The Chinese University Of Hong Kong
    08/31/20
  125. Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.EBI
    Bioorg Med Chem 18: 7849-54 (2010)
    Academia Sinica
    08/28/20
  126. Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.EBI
    Bioorg Med Chem 18: 7940-7 (2010)
    Korea Research Institute Of Bioscience And Biotechnology
    08/28/20
  127. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.EBI
    Bioorg Med Chem 17: 5139-45 (2009)
    National Human Genome Research Institute
    08/27/20
  128. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.EBI
    Bioorg Med Chem Lett 19: 2722-7 (2009)
    Kyoto Pharmaceutical University
    08/27/20
  129. Novel small-molecule inhibitors of transmissible gastroenteritis virus.EBI
    Antimicrob Agents Chemother 51: 3924-31 (2007)
    National Health Research Institute
    08/27/20
  130. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.EBI
    Bioorg Med Chem Lett 20: 1873-6 (2010)
    Korea Research Institute Of Bioscience And Biotechnology
    08/27/20
  131. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.EBI
    Bioorg Med Chem Lett 17: 5876-80 (2007)
    Purdue University
    08/24/20
  132. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.EBI
    Eur J Med Chem 150: 334-346 (2018)
    Wichita State University
    08/16/20
  133. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.EBI
    Bioorg Med Chem 24: 3035-3042 (2016)
    Academia Sinica
    09/14/17
  134. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia.BDB
    J Enzyme Inhib Med Chem 29: 59-63 (2014)
    Gyeongsang National University
    08/28/17
  135. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.BDB
    ACS Chem Biol 10: 1456-65 (2015)
    University Of Illinois At Chicago
    10/15/15
  136. Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid- hydrolysis.EBI
    Eur J Med Chem 79: 184-93 (2014)
    University Of Lille
    02/07/15
  137. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.EBI
    Bioorg Med Chem Lett 18: 732-7 (2008)
    Glaxosmithkline
    05/21/13
  138. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases.EBI
    Bioorg Med Chem 20: 5928-35 (2012)
    Korea Research Institute Of Bioscience And Biotechnology
    05/17/13
  139. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.BDB
    J Biol Chem 284: 7646-55 (2009)
    National Yang-Ming University
    10/29/12
  140. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.EBI
    Bioorg Med Chem Lett 21: 4860-4 (2011)
    Philipps University Marburg
    03/23/12
  141. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.EBI
    Bioorg Med Chem Lett 21: 3088-91 (2011)
    Chonnam National University
    12/04/11
  142. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.BDB
    Chem Biol 13: 261-8 (2006)
    Academia Sinica
    07/07/11
  143. Phage-encoded combinatorial chemical libraries based on bicyclic peptides.EBI
    Nat Chem Biol 5: 502-7 (2009)
    Laboratory Of Molecular Biology, Medical Research Council
    06/10/11
  144. Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.EBI
    Bioorg Med Chem Lett 19: 4538-41 (2009)
    Konkuk University
    08/27/10
  145. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.EBI
    Bioorg Med Chem Lett 19: 1636-8 (2009)
    Konkuk University
    01/11/10
  146. Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.EBI
    Bioorg Med Chem Lett 18: 1681-7 (2008)
    Glaxosmithkline
    11/11/09
  147. Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors.EBI
    J Med Chem 48: 6767-71 (2005)
    Purdue University
    11/10/09
  148. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.EBI
    J Med Chem 50: 1850-64 (2007)
    University Of Alberta
    11/10/09
  149. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors.EBI
    J Med Chem 49: 3440-3 (2006)
    Peking University
    11/10/09
  150. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors.EBI
    Bioorg Med Chem Lett 15: 3058-62 (2005)
    Development Center For Biotechnology
    11/10/09
  151. Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease.BDB
    J Med Chem 52: 5228-40 (2009)
    Purdue University
    09/14/09
  152. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.BDB
    Bioorg Med Chem 16: 4138-49 (2008)
    University Of Mississippi
    07/08/08
  153. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies.BDB
    J Med Chem 49: 3485-95 (2006)
    National Tsing Hua University
    09/26/06
  154. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.BDB
    Bioorg Med Chem 13: 5240-52 (2005)
    National Taiwan University
    09/26/06
  155. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease.BDB
    J Med Chem 49: 5154-61 (2006)
    National Defense Medical Center
    09/26/06
  156. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease.BDB
    J Med Chem 48: 4469-73 (2005)
    National Taiwan University
    09/26/06
  157. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor.BDB
    J Med Chem 49: 4971-80 (2006)
    Taigen Biotechnology
    09/23/06
BDB Curated by BindingDB
ChEMBL Curated by ChEBML